Trevi Therapeutics, Inc. — Form D/A

Trevi Therapeutics, Inc. of NEW HAVEN, CT, a company, filed a Form D amendment with the SEC on 2018-09-05. The offering totals $61.9M, of which $51.9M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (21)

NameRoleLocation
Mette Kirstine AggerDirectorCAMBRIDGE, MA
Ed L MathersDirectorNew Haven, CT
David R MeekerDirectorNew Haven, CT
Annie L MitsakDirectorNew Haven, CT
Eran L NadavDirectorNew Haven, CT
Thomas R SciasciaExecutive OfficerNew Haven, CT
Chris Kirstine SeiterExecutive OfficerNew Haven, CT
Michael L HeffernanDirectorNew Haven, CT
Thomas L SciasciaExecutive OfficerNew Haven, CT
David L MeekerDirectorNew Haven, CT
James L CassellaDirectorNew Haven, CT
Dominick L ColangeloDirectorNew Haven, CT
Jennifer L GoodDirectorNew Haven, CT
Jennifer L GoodExecutive OfficerNew Haven, CT
William L ForbesExecutive OfficerNew Haven, CT
Edward L MathersDirectorNew Haven, CT
Anne L VanLentDirectorNew Haven, CT
Lisa L DelfiniExecutive OfficerNew Haven, CT
Joseph R SorrentinoExecutive OfficerHammondsport, NY
Cayce L DentonDirectorNew Haven, CT
Otello Kirstine StampacchiaDirectorNew Haven, CT

Other filings by this issuer (5)

FiledFormOfferingSold
2022-04-18D$55.0M$55.0M
2021-10-21D$3.0M$3.0M
2021-10-20D$11.8M$11.8M
2017-07-24D$66.7M$41.1M
2012-12-18D$13.1M$6.6M

More